MAA
ESPR

Managed Account Advisors’s Esperion Therapeutics ESPR Stock Holding History

Managed Account Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$37K Buy
454
+3
+0.7% +$294 ﹤0.01% 2700
2015
Q1 		$42K Buy
451
+72
+19% +$4.65K ﹤0.01% 2632
2014
Q4 		$15K Buy
379
+157
+71% +$4.81K ﹤0.01% 2590
2014
Q3 		$5K Buy
+222
New +$3.53K ﹤0.01% 2624

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Managed Account Advisors's ESPR Position: Q2 2015 in Review

Managed Account Advisors increased its Esperion Therapeutics (ESPR) stake by 0.67% in Q2 2015, buying an estimated $294 and bringing the position to 454 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #2700.

Managed Account Advisors first reported a position in ESPR in Q3 2014 and has held it in 4 quarters since. The position peaked at $42K in Q1 2015. 151 funds tracked by Wall St. Rank hold ESPR as of Q2 2015.

  • Managed Account Advisors held 454 shares of Esperion Therapeutics worth $37K as of Q2 2015.
  • Managed Account Advisors bought 3 Esperion Therapeutics shares in Q2 2015, an estimated $294.
  • Esperion Therapeutics made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2700 holding.
  • Managed Account Advisors first reported a position in Esperion Therapeutics in Q3 2014 and has held it in 4 quarters since.
  • Managed Account Advisors's Esperion Therapeutics position peaked at $42K in Q1 2015.
  • 151 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.